LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $112.60.

A number of equities analysts have recently weighed in on LMAT shares. Wells Fargo & Company upped their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Barrington Research reiterated an “outperform” rating and issued a $120.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Weiss Ratings upgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 20th. Finally, Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT opened at $92.34 on Friday. The company has a market cap of $2.11 billion, a P/E ratio of 34.07, a price-to-earnings-growth ratio of 2.57 and a beta of 0.54. LeMaitre Vascular has a 12-month low of $79.00 and a 12-month high of $118.01. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The company’s fifty day moving average is $104.42 and its two-hundred day moving average is $96.04.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.02. The firm had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.LeMaitre Vascular’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities analysts expect that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st were paid a $0.25 dividend. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.1%. LeMaitre Vascular’s dividend payout ratio is 36.90%.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer directly owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the transaction, the director directly owned 3,942 shares in the company, valued at approximately $437,956.20. The trade was a 56.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Sound Income Strategies LLC increased its stake in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new position in shares of LeMaitre Vascular during the 1st quarter worth $32,000. MAI Capital Management acquired a new position in LeMaitre Vascular during the third quarter worth $38,000. Geneos Wealth Management Inc. increased its position in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the second quarter worth $47,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.